Irritable bowel syndrome. Irritable bowel syndrome with diarrhea
Conditions
Interventions
Intervention 1: Intervention group: In this group, patients will receive Montelukast 10 mg tablets produced by Abidi Pharmaceutical Company once a day for 4 weeks plus their standard treatment, which
Sponsors
Islamic Azad University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) based on the Rome IV criteria Age between 18-65 years old Informed consent
Exclusion criteria
Exclusion criteria: Patients with psychiatric disorders, kidney failure, celiac disease, and inflammatory bowel disease (IBD). People who suffer from depression. Pregnancy and lactation History of drug allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal Pain (Severity of pain and Duration of pain). Timepoint: Before intervention and 4 weeks after intervention and 8 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Abdominal distension (Bloating, Swollen or Tight tummy). Timepoint: Before intervention and 4 weeks after intervention and 8 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Satisfaction with fecal excretion. Timepoint: Before intervention and 4 weeks after intervention and 8 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;The impact of the IBS on the Patient's Quality of Life. Timepoint: Before intervention and 4 weeks after intervention and 8 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS).;Irritable Bowel Syndrome Severity Score. Timepoint: Before intervention and 4 weeks after intervention and 8 weeks after intervention. Method of measurement: Irritable Bowel Severity Scale (IBSS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Amirpasha Tabaeian
Iran University of Medical Sciences
Outcome results
None listed